SODIUM SULFACETAMIDE AND SULFUR- sulfacetamide sodium, sulfur liquid 
Method Pharmaceuticals, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

Sodium Sulfacetamide 10% - Sulfur 5% Cleanser

Rx Only

DESCRIPTION

Each gram of sodium sulfacetamide 10% and sulfur 5% cleanser contains
100 mg of sodium sulfacetamide and 50 mg of sulfur in a cleanser
containing Aloe Vera leaf Extract, Butylated Hydroxytoluene, Cetyl Alcohol,
Citric Acid, Cocamidopropyl Betaine, Disodium EDTA, Glycerin, Glyceryl
Stearate SE, PEG-100 Stearate, Phenoxyethanol, Purified Water, Sodium
laureth sulfate, Sodium Thiosulfate, Stearyl alcohol, Triacetin, Xanthan Gum.

Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Sodium sulfacetamide is C 8H 9N 2NaO 3S·H2O with molecular weight of 254.24. Chemically, it is N-[(4-aminophenyl)sulfonyl]-acetamide, monosodium salt, monohydrate.

The structural formula is:

struct

CLINICAL PHARMACOLOGY

The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours.
The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.

INDICATIONS

SODIUM SULFACETAMIDE 10% - SULFUR 5% CLEANSER is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

CONTRAINDICATIONS:

Sodium Sulfacetamide 10% & Sulfur 5% Cleanser is contraindicated in persons with know or suspected hypersensitivity to
sulfonamides, sulfur or any other component of this preparation. Sodium
Sulfacetamide 10% & Sulfur 5% Cleanser is not to be used by patients with
kidney disease.

WARNINGS

Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.
Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEEP OUT OF REACH OF CHILDREN.

NOTICE: Protect from freezing and excessive heat. The product may tend to
darken slightly on storage. Slight discoloration does not impair the efficacy
or safety of the product. Keep bottle tightly closed.


Occasionally, a slight discoloration of fabric may occur when an excessive
amount of the product is used and comes in contact with white fabrics.
This discoloration, however, presents no problem, as it is readily removed
by ordinary laundering without bleaches.

DOSAGE AND ADMINISTRATION

USE: Wash affected area once or twice daily, or as
directed by your physician. Avoid contact with eyes or mucous membranes.
Wet skin and liberally apply to areas to be cleansed, massage gently into
skin for 10-20 seconds working into a full lather, rinse thoroughly and pat
dry. If drying occurs, it may be controlled by rinsing cleanser off sooner or
using less often. See label booklet for Full Prescribing Information.
FOR EXTERNAL USE ONLY. NOT FOR INTRAVAGINAL OR OPHTHALMIC
USE. (KEEP AWAY FROM EYES).
KEEP OUT OF REACH OF CHILDREN.

Package Label

label

label

label

label

label

SODIUM SULFACETAMIDE AND SULFUR 
sulfacetamide sodium, sulfur liquid
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:58657-472
Route of AdministrationTOPICAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
SULFACETAMIDE SODIUM (UNII: 4NRT660KJQ) (SULFACETAMIDE - UNII:4965G3J0F5) SULFACETAMIDE SODIUM100 mg  in 1 g
SULFUR (UNII: 70FD1KFU70) (SULFUR - UNII:70FD1KFU70) SULFUR50 mg  in 1 g
Inactive Ingredients
Ingredient NameStrength
BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
ALOE VERA LEAF (UNII: ZY81Z83H0X)  
1-ETHYL CITRATE (UNII: Y7R23627P5)  
CETYL ALCOHOL (UNII: 936JST6JCN)  
EDETATE DISODIUM (UNII: 7FLD91C86K)  
GLYCERYL STEARATE SE (UNII: FCZ5MH785I)  
PEG-100 STEARATE (UNII: YD01N1999R)  
COCAMIDOPROPYL BETAINE (UNII: 5OCF3O11KX)  
TRIACETIN (UNII: XHX3C3X673)  
WATER (UNII: 059QF0KO0R)  
SODIUM THIOSULFATE (UNII: HX1032V43M)  
SODIUM LAURYL SULFATE (UNII: 368GB5141J)  
STEARYL ALCOHOL (UNII: 2KR89I4H1Y)  
XANTHAN GUM (UNII: TTV12P4NEE)  
GLYCERIN (UNII: PDC6A3C0OX)  
PHENOXYETHANOL (UNII: HIE492ZZ3T)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:58657-472-06170 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product11/15/2021
2NDC:58657-472-07170.3 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product11/15/2021
3NDC:58657-472-12340 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product11/15/2021
4NDC:58657-472-13340.2 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product11/15/2021
5NDC:58657-472-08227 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product11/15/2021
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other11/15/2021
Labeler - Method Pharmaceuticals, LLC (060216698)

Revised: 12/2021
Document Id: d35a7d76-289c-f7c4-e053-2995a90ae760
Set id: d35a7764-f3c6-fd1b-e053-2a95a90a8036
Version: 1
Effective Time: 20211217
 
Method Pharmaceuticals, LLC